Purinergic signalling and disorders of the central nervous system

Nature Reviews Drug Discovery

Volumn 7, Issue 7, 2008, Pages 575-590

  Burnstock, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR AFFECTING AGENT; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; BETA INTERFERON; BRILLIANT BLUE; CAFFEINE; COCAINE; GUANOSINE; HALOPERIDOL; IVERMECTIN; LEVODOPA; MORPHINE; PURINE P2 RECEPTOR BLOCKING AGENT; PURINE P2 RECEPTOR STIMULATING AGENT; PURINERGIC P2 RECEPTOR; PURINERGIC P2X RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC RECEPTOR; PURINERGIC RECEPTOR AFFECTING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; SURAMIN; THEOPHYLLINE; UNINDEXED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; BRAIN INJURY; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSKINESIA; EPILEPSY; HUMAN; HUNTINGTON CHOREA; MIGRAINE; MULTIPLE SCLEROSIS; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; PAIN; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION;

EID: 46449134214     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2605     Document Type: Review

References (247)

1. Burnstock, G. Purinergic nerves. Pharmacol. Rev. 24, 509-581 (1972).
2. Burnstock, G., Campbell, G., Satchell, D. & Smythe, A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br. J. Pharmacol. 40, 668-688 (1970).
3. Burnstock, G. Do some nerve cells release more than one transmitter? Neuroscience 1, 239-248 (1976).
4. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87, 659-797 (2007).
5. Burnstock, G. A basis for distinguishing two types of purinergic receptor, in Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach (eds Straub, R. W. & Bolis, L.) 107-118 (Raven Press, New York, 1978).
6. Burnstock, G. & Kennedy, C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen. Pharmacol. 16, 433-440 (1985).
7. Ralevic, V. & Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413-492 (1998).
8. Abbracchio, M. P. et al. International Union of Pharmacology. Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58 281-341 (2006).
9. Burnstock, G. Purine and pyrimidine receptors. Cellular and Molecular Life Sciences 64, 1471-1483 (2007).
10. Köles, L., Fürst, S. & Illes, P. Purine ionotropic (P2X) receptors. Curr. Pharm. Des. 13, 2368-2384 (2007).
11. North, R. A. & Verkhratsky, A. Purinergic transmission in the central nervous system. Pflugers Arch. 452, 479-485 (2006).
12. Bonan, C. D., Schetinger, M. R., Battastini, A. M. & Sarkis, J. J. Ectonucleotidases and synaptic plasticity: Implications in physiological and pathological conditions. Drug Dev. Res. 52, 57-65 (2001).
13. Burnstock, G. & Knight, G. E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240 31-304 (2004).
14. Fields, D. & Burnstock, G. Purinergic signalling in neuron-glial interactions. Nature Rev. Neurosci. 7, 423-436 (2006).
15. Inoue, K., Koizumi, S. & Tsuda, M. The role of nucleotides in the neuron-glia communication responsible for the brain functions. J. Neurochem. 102, 1447-1458 (2007).
16. Abbracchio, M. P. & Burnstock, G. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78, 113-145 (1998).
17. Mishra, S. K. et al. Extracellular nucleotide signaling in adult neural stem cells: Synergism with growth factor-mediated cellular proliferation. Development 133, 675-684 (2006).
18. Neary, J. T. et al. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19, 13-18 (1996).
19. Pankratov, Y. V., Lalo, U. V. & Krishtal, O. A. Role for P2X receptors in long-term potentiation. J. Neurosci. 22, 8363-8369 (2002).
20. Pedrazza, E. L. et al. Habituation to an open field alters ecto-nucleotidase activities in rat hippocampal synaptosomes. Neurosci. Lett. 413, 21-24 (2007).
21. Basheer, R., Strecker, R. E., Thakkar, M. M. & McCarley, R. W. Adenosine and sleep-wake regulation. Prog. Neurobiol. 73, 379-396 (2004).
22. 2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res. Bull. 31, 397-404 (1993).
23. 2R purinergic receptor subunit mRNA and protein are expressed by all hypothalamic hypocretin/orexin neurons. J. Comp. Neurol. 498, 58-67 (2006).
24. Brockhaus, J., Dressel, D., Herold, S. & Deitmer, J. W. Purinergic modulation of synaptic input to Purkinje neurons in rat cerebellar brain slices. Eur. J. Neurosci. 19, 2221-2230 (2004).
25. Kittner, H., Krügel, U., Hoffmann, E. & Illes, P. Modulation of feeding behaviour by blocking purinergic receptors in the rat nucleus accumbens: A combined microdialysis, electroencephalographic and behavioural study. Eur. J. Neurosci. 19, 396-404 (2004).
26. 1 receptors in rats: Modulation of feeding behaviour by extracellular nucleotides. Eur. J. Neurosci. 24, 2049-2056 (2006).
27. Franke, H., Krügel, U. & Illes, P. P2 receptors and neuronal injury. Pflugers Arch. 452, 622-644 (2006).
28. Neary, J. T., Kang, Y., Tran, M. & Feld, J. Traumatic injury activates protein kinase B/Akt in cultured astrocytes: Role of extracellular ATP and P2 purinergic receptors. J. Neurotrauma 22, 491-500 (2005).
29. Neary, J. T. et al. P2 receptor signalling, proliferation of astrocytes, and expression of molecules involved in cell-cell interactions. Novartis Found. Symp. 276, 131-143 (2006).
30. Tran, M. D. & Neary, J. T. Purinergic signaling induces thrombospondin-1 expression in astrocytes. Proc. Natl Acad. Sci. USA. 103, 9321-9326 (2006).
31. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nature Neurosci. 8, 752-758 (2005).
32. Färber. K. & Kettenmann, H. Purinergic signaling and microglia. Pflugers Arch. 452, 615-621 (2006).
33. Neary, J. T., Kang, Y., Willoughby, K. A. & Ellis, L. F. Activation of extracellular signal-regulated kinase by stretch-induced injury in astrocytes involves extracellular ATP and P2 purinergic receptors. J. Neurosci. 23, 2348-2356 (2003).
34. 12 receptor regulates microglial activation by extracellular nucleoticles. Nature Neurosci. 9 1512-1519 (2006).
35. 12 receptors in ATP-induced microglial chemotaxis. Glia 55, 604-616 (2007).
36. Xiang, Z. et al. Microglial morphology and its transformation after challenge by extracellular ATP in vitro. J. Neurosci. Res. 83, 91-101 (2006).
37. 6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091-1095 (2007).
38. + monocytes following experimental traumatic brain injury. Exp. Neurol. 197, 252-257 (2006).
39. 7 in microglial proliferation. J. Neurochem. 99, 745-758 (2006).
40. Franke, H. & Illes, P. Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmocol. Ther. 109, 297-324 (2006).
41. Washburn, K. B. & Neary, J. T. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation. Neuroscience 142, 411-423 (2006).
42. Brambilla, R. et al. Cyclo-oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis. Br. J. Pharmacol. 126 563-567 (1999).
43. 2 purinergic receptors in precerebellar nuclei. Neuroscience 115, 425-434 (2002).
44. 2 receptor activation: Novel pathways for neuronal survival. J. Neurosci. 26, 3798-3804 (2006).
45. Chorna, N. E. et al. P2Y. receptors activate neuroprotective mechanisms in astrocytic cells. J. Neurochem. 91, 119-132 (2004).
46. Inoue, K. ATP receptors for the protection of hippocampal functions. Jpn. J. Pharmscol. 78, 405-410 (1998).
47. Franke, H. et al. Changes in purinergic signaling after cerebral injury - involvement of glutamatergic mechanisms? Int. J. Dev. Neurosci. 24, 123-132 (2006).
48. 7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J. Neurosci. 27, 9525-9533 (2007).
49. 7 receptor inhibition improves recovery after spinal cord injury. Nature Med. 10, 821-827 (2004).
50. Sperlagh, B. et al. Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. Neuroscience 149, 99-111 (2007).
51. 2 receptor. Brain Res. 952, 31-37 (2002).
52. Lämmer, A. et al. Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral iscnaemia-induced injury in rats. Eur. J. Neurosci. 23, 2824-2828 (2006).
53. Braun, N. et al. Upregulation of the enzyme chain hydrolyzing extracellular ATP after transient forebrain ischemia in the rat. J. Neurosci. 18, 4891-4900 (1998).
54. 4 Receptor and ischemic cell death: Prevention by P2 antagonists. Neuroscience 120, 85-98 (2003)
55. Frenguelli, B. G., Wigmore, G., Llaudet, E. & Dale, N. Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J. Neurochem. 101, 1400-1413 (2007).
56. Franke, H. et al. P2X, receptor expression after ischemia in the cerebral cortex of rats. J. Neuropathol. Exp. Neurol. 63, 686-699 (2004).
57. Melani, A. et al. P2X, receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J. Cereb. Blood Flow Metab. 26, 974-982 (2006).
58. Wirkner, K, et al. Supersensitivity of P2X, receptors in cerebrocortical cell cultures after in vitro ischemia. J. Neurochem. 95, 1421-1437 (2005).
59. Le Feuvre, R. A., Brough, D., Touzani, O., & Rothwell, N. J. Role of P2X, receptors in ischemic and excitatoxic brain injury in vivo. J. Cereb. Blood Flow Metab. 23, 381-384 (2003).
60. Cavaliere, F, Dinkel, K. & Reymann, K. Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage. Neuroscience 136, 615-623 (2005).
61. Zhang, Y., Deng, P., Li, Y. & Xu, Z. C. Enhancement of excitatory synaptic transmission in spiny neurons after transient forebrain ischemia. J. Neurophysiol. 95, 1537-1544 (2006).
62. Schock, S. C. et al. Cortical spreading depression releases ATP into the extracellular space and purinergic receptor activation contributes to the induction of ischemic tolerance. Brain Res. 1168, 129-138 (2007).
63. Pedata, F. et al. The role of ATP and adenosine in the brain under normoxic and ischemic conditions. Purinergic Signal. 3, 299-310 (2007).
64. Chen, H. H. et al. Extracellular ATP-dependent upregulation of the transcription cofactor LMO4 promotes neuron survival from hypoxia. Exp. Cell Res. 313, 3106-3116 (2007).
65. Briede, J. & Duburs, G. Protective effect of cerebrocrast on rat brain ischaemia induced by occlusion of both common carotid arteries. Cell Biochem. Funct. 25, 203-210 (2007).
66. Volonté, C. et al. Extracellular ATP and neurodegeneration. Curr. Drug Targets. CNS Neurol. Disord. 2, 403-412 (2003).
67. Watanabe, S., Yoshimi, Y. & Ikekita, M. Neuroprotective effect of adenine on purkinje cell survival in rat cerebellar primary cultures. J. Neurosci. Res. 74, 754-759 (2003).
68. Ogata, T. et al. Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors. Brain Res. 981, 174-183 (2003).
69. Purcell, W. M. & Atterwill, C. K. Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives. Neurochem. Res. 20, 521-532 (1995).
70. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127, 1075-1084 (2004).
71. Ismavilova, N., Crossman, A., Verkhratsky, A. & Brotrhie J. Effects of adenosine A, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats. Eur. J. Pharmacol. 497, 187-195 (2004).
72. 2A receptors in Parkinson's disease and other CNS disorders. Prog. Neurobiol. 83, 261-347 (2007).
73. Jun, D. & Kim. K. ATP-mediated necrotic volume increase (NVI) in substantia nigra pars compacta dopaminergic neuron. Society for Neuroscience Washington, DC. Abstr. 222, 18 (2004).
74. Heine, C. et al. P2 receptor expression in the dopaminergic system of the rat brain during development. Neuroscience 149, 165-181 (2007).
75. Morales, I. et al. Substantia nigra osmoregulation: Taurine and ATP involvement. Am. J. Physiol. Cell Physiol. 292, C1934-C1941 (2007).
76. Jacobson, K. A. et al. Agonists and antagonists for P2 receptors, in Novortis Foundation Symposium 276 Purinergic Signalling in Neuron-Clial Interoctions, 58-68 (John Wiley & Sons Ltd., Chichester, 2006).
77. 2 production in astrocytes: regulation by cytokines, extracellular ATP, and oxiditive agents. Prostaglandins Leukot. Essent. Fatty Acids 69, 437-448 (2003)
78. 7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem. 278, 13309-13317 (2003).
79. 7 receptor in Alzheimer disease and amyloid-β peptide-treated microglia and in peptide-injected rat hippocampus. J. Neuropathol. Exp. Neurol. 65, 1090-1097 (2006).
80. 7 receptor modulation of β-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J. Neuroimmunol. 147, 56-61 (2004).
81. Tumini, E. et al. The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients Hum. Psychopharmacol. 22, 75-80 (2007).
82. 1 purinergic receptor in Alzheimer's disease. Neuroreport 11, 3799-3803 (2000).
83. 2 nucleotide receptors enhance α-secretase-dependent amyloid precursor protein processing. J. Biol. Chem. 280, 18696-18702 (2005).
84. McLarnon, J. G. et al. Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. J. Neurosci. Res. 81, 426-435 (2005).
85. 1 receptors are decreased in Alzheimer's disease. Neurosci. Lett. 118, 257-260 (1990).
86. 1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 13, 440-451 (2003).
87. Martinez-Mir, M. I., Probst, A. & Palacios, J. M. Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 42, 697-706 (1991).
88. 2A receptor blockade prevents EEG and motor abnormalities in a rat model of Huntington's disease. Drug Dev. Res. 50, 69 (2000)
89. Bauer, A. et al. Striatal loss of A1 adenosine receptors in Huntington's disease - a PET study. J. Neural Transm. 114, XXI (2007).
90. 2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23, 44-53 (2006).
91. 2A receptors in Huntington's disease. Prog. Neurobiol. 81, 331-348 (2007).
92. Diez-Zaera, M. et al. Purinergic system in Huntington's disease: development of new therapeutic strategies. J. Neurochem. 101 S66 (2007).
93. Andries, M., Van Damme, P., Robberecht, W. & Van Den Bosch, L. Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 25, 8-16 (2007).
94. 2 purinergic receptors in facial motoneurons after nerve lesions in rodents and correlation with motoneuron degeneration. Neurobiol. Dis. 25, 121-133 (2007).
95. Trudeau, F., Gagnon, S. & Massicotte, G. Hippocampal synaptic plasticity and glutamate receptor regulation: Influences of diabetes mellitus. Eur. J. Pharmacol. 490, 177-186 (2004).
96. Cox, D. J. et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 28, 71-77 (2005).
97. Duarte, J. M., Oses, J. P., Rodrigues, R. J. & Cunha, R. A. Modification of purinergic signaling in the hippocampus of streptozotocin induced didbetic rats. Neuroscience 149, 382-391 (2007).
98. Lucas, S. M., Rothwell, N. J. & Gibson, R. M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147, S232-S240 (2006).
99. Bours, M. J. et al. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358-404 (2006).
100. Sperlagh, B. & Illes, P. Purinergic modulation of microglial cell activation. Purinergic Signal. 3, 117-127 (2007).
101. Marchand, F., Perretti, M. & McMahon, S. B. Role of the immune system in chronic pain. Nature Rev. Neurosci. 6, 521-532 (2005).
102. Moalem, G. & Tracey, D. J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51, 240-264 (2006).
103. 7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J. Biol. Chem. 274, 13205-13210 (1999).
104. Potucek, Y. D., Crain, J. M. & Watters, J. J. Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression. Neurochem. Int. 49, 204-214 (2006).
105. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417-426 (2002).
106. 7 and the inflammasome. Trends Pharmacol. Sci. 28, 465-472 (2007).
107. 7 receptor-activated microglia. J. Neurosci. 24, 1-7 (2004).
108. 7 receptor in the formation of multinucleated giant cells. J. Immunol. 177 7257-7265 (2006).
109. 7 receptor activation in mouse microglial cells. J. Neurochem. 102, 1518-1532 (2007).
110. Takenouchi, T. et al. Prion infection correlates with hypersensitivity of P2X7 nucleotide receptor in a mouse microglial cell line. FEBS Lett. 581, 3019-3026 (2007).
111. 4 receptor by lesional activated microglia during formalin-induced inflammatory pain. J. Neuroimmunol. 163, 120-127 (2005).
112. 7 ATP receptors following LPS-induced activation. Neuropharmacology 53, 496-504 (2007).
113. Abbracchio, M. P. & Verderio, C. Pathophysiological roles of P2 receptors in glial cells, in Novartis Foundation Symposium 276 Purinergic Signalling in Neuron-Glial Interactions 91-103 (John Wiley & Sons Ltd., Chichester, 2006).
114. 7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J. Neurosci. 21, 7135-7142 (2001).
115. Agresti, C. et al. ATP regulates oligodendrocyte progenitor migration, proliferation, and differentiation: Involvement of metabotropic P2 receptors. Brain Res. Brain Res. Rev. 48, 157-165 (2005).
116. 7 receptor expression and function in human astrocytes. Glia 49 245-258 (2005).
117. Spanevello, R. M. et al. Apyrase and 5′ nucleotidase activities in synaptosomes from the cerebral cortex of rats experimentally demyelinated with ethidium bromide and treated with interferon-β. Neurochem. Res. 31, 455-462 (2006).
118. + macrophages in rat CNS during experimental autoimmune encephalomyelitis. Neuroscience 134, 199-205 (2005).
119. -/- mice: Evidence for loss of apoptotic activity in lymphocytes. J. Immunol. 176, 3115-3126 (2006).
120. + Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225-1232 (2007).
121. Knutsen, L. J. S. & Murray, T. F. Adenosine and ATP in epilepsy, in Purinergic Approaches in Experimental Therapeutics (eds Jacobson, K. A. & Jarvis, M. F.) 423-447 (Wiley-Liss, New York, 1997).
122. Ross, F. M., Brodie, M. J. & Stone, T. W. Modulation by adenine nucleotides of epileptiform activity in the CA3 region of rat hippocampal slices. Br. J. Pharmacol. 123, 71-80 (1998).
123. Vianna, E. P. et al. Evidence that ATP participates in the pathophysiology of pilocarpine-induced temporal lobe epilepsy: fluorimetric, immunohistochemical, and Western blot studies. Epilepsia 43, 227-229 (2002).
124. 7 receptor immunareactive profile confined to resting and activated microglia in the epileptic brain. Brain Res. 1089, 171-178 (2006).
125. Wieraszko, A. & Seyfried, T. N. Increased amount of extracellular ATP in stimulated hippocampal slices of seizure prone mice. Neurosci. Lett. 106, 287-293 (1989).
126. Slézia, A. et al. Uridine release during aminopyridine-induced epilepsy. Neurobiol. Dis 16, 490-499 (2004).
127. Nicolaidis, R., Bruno, A. N., Sarkis, J. J. & Souza, D. O. Increase of adenine nucleciticle hydrolysis in rat hippocampal slices after seizures induced by quinolinic acid. Neurochem. Res. 30, 385-390 (2005).
128. Oses, J. P. Modification by kainate-induced convulsions of the density of presynaptic P2X receptors in the rat hippocampus. Purinergic Signal. 2, 252-253 (2006).
129. Tian, G. F. et al. An astrocytic basis of epilepsy. Nature Med. 11, 973-981 (2005).
130. Dragunow, M. Purinergic mechanisms in epilepsy. Prog. Neurrobiol. 31, 85-108 (1988).
131. 2A receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled seizures in rats. Seizure 15, 41-48 (2006).
132. CO2 to cortical excitability via pH. Neuron 48, 1011-1023 (2005).
133. Ekonomou, A., Angelatou, F, Vergnes, M. & Kostopoulos, G. Lower density of A1 adenosine receptors in nucleus reticularis thalami in rats with genetic absence epilepsy. Neuroreport 9, 2135-2140 (1998).
134. Machado-Vieira, R., Lara, D. R., Souza, D. O. & Kapczinski, F. Purinergic dysfunction in mania: An integrative model. Med. Hypotheses 58, 297-304 (2002).
135. Lam, P., Hong, C. J. & Tsai. S. J. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci. Lett. 378, 98-101 (2005).
136. Williams, M. Purinergic receptors and central nervous system function, in Psychophormacology: The Third Generation of Progress (ed. Meltzer, H. Y.) 289-301 (Raven Press, New York, 1987).
137. Ward, R. R & Dorsa, D. M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-HT4 or 5-HT6 receptors following antipsychotic administration. Neuroscience 89, 927-938 (1999).
138. 2A adenosine receptors. Neuroscience 97, 195-204 (2000).
139. Judelson, D. A. et al. Effect of chronic caffeine intake on choice reaction time, mood, and visual vigilance. Physiol. Behav 85 629-634 (2005).
140. Wagner, J. A. & Katz, R. J. Purinergic control of anxiety: Direct behavioral evidence in the rat. Neurosci. Lett. 43, 333-337 (1983).
141. 1 receptor. Proc. Natl Acad. Sci. USA. 98, 9407-9412 (2001).
142. 1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: Implications for the involvement of P2Y receptor-mediated nitric oxide production. Neuropsychophormacology 28, 435-444 (2003).
143. Vinade, E. R. et al. Chronically administered guarosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res. 977 91-102 (2003).
144. 2A receptors. Neurosci. Lett. 355, 21-24 (2004).
145. Alesci, S. et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 90, 2522-2530 (2005).
146. Lucae, S. et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum, Mol. Genet. 15, 2438-2445 (2006).
147. Barden, N. et al. Analysis of single nucleoticle polymorphismis in genes in the chromosome 12024.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 374-382 (2006).
148. Busnello, J. V. et al. Acute and chronic electroconvulsive shock in rats: Effects on peripheral markers of neuronal injury and glial activity. Life Sci. 78, 3013-3017 (2006).
149. Ushijima, I. et al. Effects of dilazep (Comelian) on the central purinergic system: Inhibitory effects on clondine-induced aggressive behavior. Eur. J. Pharmacol. 161, 245-248 (1989).
150. Zou, C. J., Onaka. T. O. & Yagi, K. Effects of suramin on neuroendocrine and behavioural responses to conditioned fear stimuli. Neuroreport 9, 997-999 (1998).
151. 1 receptor activation selectively impairs the acquisition of contextual fear conditioning in rats. Behav Neurosci. 115, 1283-1290 (2001).
152. Krügel, U. et al. P2 receptors are involved in the mediation of motivation-related behavior. Purinergic Signal. 1, 21-29 (2004).
153. 2A receptors. Neuropsychopharmacology 31, 525-534 (2006).
154. Van Calker, D. & Biber, K. The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders. Neurochem. Res. 30, 1205-1217 (2005).
155. Inoue, K., Koizumi, S. & Ueno, S. Implication of ATP receptors in brain functions. Prog, Neurobiol. 50, 483-492 (1996).
156. Lara, D. R., Dall'lgna, O. P., Ghisolfi, E. S. & Brunsstein, M. G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 617-629 (2006).
157. 2 receptor interactions in animal models of schizophrenia. Eur. Jr. Pharmacol. 295, 147-154 (1996).
158. Tsai, S. J. Adenosine A2a receptor/dopamine D2 receptor hetero-oligomerization: A hypothesis that may explain behavioral sensitization to psychostimulants and schizophrenia. Med. Hypotheses 64, 197-200 (2005).
159. Lara, D. R. & Souza, D. O. Schizophrenia: A purinergic hypothesis. Med. Hypotheses 54, 157-166 (2000).
160. Deckert, J. et al. Up-regulation of striatal adenosine A. receptors in schizophrenia. Neuroreport 14, 313-316 (2003).
161. Yee, B. K. et al. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur. J. Neurosci. 26, 3237-3252 (2007).
162. 1 receptor expression in the brain after sensitisation with d-amphetamine. Psychopharmacology (Berl) 167, 187-194 (2003).
163. 4 receptor subtypes expressed in Xenopus oocytes. Neuropharmacology 49, 243-253 (2005).
164. Burnstock, C. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol. Sci. 22, 182-188 (2001).
165. Burnstock, G. Purinergic P2 receptors as targets for novel analgesics. Pharmacol. Therap. 110, 433-454 (2006).
166. 3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 99, 11-19 (2002).
167. Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004).
168. 2X receptors mediate fast synaptic transmission in the dorsal horn of the rat spinal cord. J. Neurosci. 17, 5297-5304 (1997).
169. Jo, Y. H. & Schlichter, R. Synaptic corelease of ATP and GABA in cultured spinal neurons. Nature Neurosci. 2, 241-245 (1999).
170. 4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424, 778-783 (2003).
171. McGaraughty, S. & Jarvis, M. F. Purinergic control of neuropathic pain. Drug Dev. Res. 67, 376-388 (2006).
172. Inoue, K. P2 receptors and chronic pain. Purinergic Signal. 3 135-144 (2007).
173. Scholz, J. & Woolf, C. J. The neuropatinic pain triad: Neurons, immune cells and glia. Nature Neurosci. 10, 1361-1368 (2007).
174. Coull, J. A. et al. BDNF from microglia the shift in neuronal anion gradient uaderlying neuropathic pain. Nature 438, 1017-1021 (2005).
175. 4. a key molecule for mechanical allodynia. Glia 53, 769-775 (2006).
176. Guo, L. H., Guo, K. T., Wendel, H. P. & Schluesener, H. J. Combinations of TLR and NOD2 ligands stimulate rat microglial P2X4R expression. Biochem. Biophys. Res. Commun. 349, 1156-1162 (2006).
177. Tsuda, M. et al. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45, 89-95 (2004).
178. Morita, K. et al. Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice. Pain 111, 351-359 (2004).
179. Inoue, K. ATP receptors of microglia involved in pain, in Novartis Foundation Symposium 276 Purinergic Signalling in Neuron-Glial Interactions 263-274 (John Wiley & Sons Ltd., Chichester, 2006).
180. Trang, T., Beggs, S. & Salter, M. W. Purinoceptors in microglia and neuropathic pain. Pflugers Arch. 452, 645-652 (2006).
181. 7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114 386-396 (2005).
182. 4 in pain processing; common or divergent pathways? Purinergic Signai. 2 46-47 (2006).
183. 7 heteromeric receptors. Mol. Pharmacol. 12, 1447-1456 (2007).
184. Okada, M., Nakagawa, T., Minami, M. & Satoh, M. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J. Pharmacol. Exp. Ther. 303, 66-73.(2002).
185. 4 receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochem. Cell Biol. 120, 415-426 (2003).
186. Gerevich, Z. & Illes, P. P2Y receptor. and pain transmission. Purinergic Signal. 1, 3-10 (2004).
187. Selden, N. R. et al. Purinergic actions on neurons that modulate nociception in the rostral ventromedial medulla. Neuroscience 146, 1808-1816 (2007).
188. 3 receptor-channels via G protein-dependent facilitation of their desensitization. Br. J. Pharmacol. 151, 226-236 (2007).
189. Nakagawa, T. et al. Intrathecal administration of ATP produces long-lasting allodynia in rats: Differential mechanisms in the phase of the induction and maintenance. Neuroscience 147, 445-455 (2007).
190. 3 receptors in neuropathic pain in a mouse model of chronic constriction injury. Drug Dev. Res. 59, 104-111 (2003).
191. 2 activation in primary afferent sensory neurons contributes to neuropathic pain. J. Neurochem. 103, 1408-1416 (2007).
192. Chen, Y. et al. Mechanisms underlying enhanced P2X receptor-mediated responses in the neuropathic pain state. Pain 119, 38-48 (2005).
193. 2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.
194. 3 receptor involvement in pain states. Mol. Neurobiol. 36, 165-183 (2007).
195. 7 in pain and inflammation. Purinergic Signal. 3, 163-169 (2007).
196. 7-related modulation of pathological nociception in rats. Neuroscience 146, 1817-1828 (2007).
197. McQuay, H. J. et al. A systematic review of anti-depressants in neuropathic pain. Pain 68, 217-227 (1996).
198. Pedrazza, E. L. et al. Sertraline and clomipramine inhibit nucleotide catabolism in rat brain synaptosomes. Toxicol. In Vitro 21, 671-676 (2007).
199. Akkari, R., Burbiel, J. C., Hockemeyer, J. & Müller, C. E. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr. Top. Med. Chem. 6, 1375-1399 (2006).
200. Burnstock, G. The role of adenosine triphosphate in migraine. Biomed. Pharmacother. 43, 727-736 (1989).
201. 3 receptor expression differs from dorsal root ganglion and is modulated by deep tissue inflammation. Pain 117, 280-291 (2005).
202. 3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J. Neurosci. 26, 6163-6171 (2006).
203. Chen, C. C. et al. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377, 428-431 (1995).
204. Fumagalli, M., Ceruti, S., Verderio, C. & Abbracchio, M. P. ATP as a neurotransmitter of pain in migraine: A functional role for P2Y receptors in primary cultures from mouse trigeminal sensory ganglia. Purinergic Signal. 2, 120-121, (2006).
205. 3 receptors of nociceptive trigeminal ganglion neurons. J. Neurosci. 27, 8190-8201 (2007).
206. Shapiro, R. E. Caffeine and headaches. Neurol. Sci. 28, S179-S183 (2007).
207. Humphrey, P. P. A. The discovery of a new drug class for the acute treatment of migraine. Headache 47, S10-S19 (2007).
208. 2A receptor gene haplotype is associated with migraine with aura. Cephalalgia 27, 177-181 (2007).
209. Gever, J. et al. Pharmacology of P2X channels. Pflugers Arch. 452, 513-537 (2006).
210. Wilot, L. C. et al. Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem. Res. 32, 1539-1546 (2007).
211. Chang, G., Chen, L. & Mao, J. Opiod tolerance and hyperalgesia. Med. Clin. North Am. 91, 199-211 (2007).
212. Ho, B. T. et al. Analgesic activity of anticancer agent suramin. Anticancer Drugs 3, 91-94 (1992).
213. Fellin, T. et al. Bidirectional astrocyte-neuron communication: the many roles of glutamate and ATP, in Novartis Foundation Symposium 276 Purinergic Signalling in Neuron-Glial Interactions 208-221 (John Wiley & Sons Ltd., Chichester, 2006).
214. 7 receptors exert a permissive role on the activation of release-enhancing presynaptic α7 nicotinic receptors co-existing on rat neocortex glutamatergic terminals. Neuropharmacology 50, 705-713 (2006).
215. 4 receptors in the rat hippocampus. J. Neurosci. 25, 6286-6295 (2005).
216. Pankratov, Y., Lalo, U., Verkhratsky, A. & North, R. A. Vesicular release of ATP at central synapses. Pflugers Arch. 452, 589-597 (2006).
217. Bodin, P. & Burnstock, G. Purinergic signalling: ATP release. Neurochem. Res. 26, 959-969 (2001).
218. Montana, V. et al. Vesicular transmitter release from astrocytes. Glia 54, 700-715 (2006).
219. Zhang, Z. et al. Regulated ATP release from astrocytes through lysosome exocytosis. Nature Cell Biol. 9, 945-953 (2007).
220. Stout, C. E., Costantin, J. L., Naus, C. C. & Charles, A. C. Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J. Biol. Chem. 277, 10482-10488 (2002).
221. Wall, M. J. & Dale, N. Auto-inhibition of rat parallel fibre-Purkinje cell synapses by activity-dependent adenosine release. J. Physiol. 581, 553-565 (2007).
222. Martín, E. D. et al. Adenosine released by astrocytes contributes to hypoxia-induced modulation of synaptic transmission. Glia 55, 36-45 (2007).
223. Zimmermann, H. et al. Ecto-nucleotidases, molecular properties and functional impact. An. R. Acad. Nac. Farm. 73, 537-566 (2007).
224. Burnstock, G. & Wood, J. N. Purinergic receptors: Their role in nociception and primary afferent neurotransmission. Curr. Opin. Neurobiol. 6, 526-532 (1996).
225. Sperlágh, B., Zsilla, G., Baranyi, M., Illes, P. & Vizi, E. S. Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. Neuroscience 149, 99-111 (2007).
226. Ribeiro, J. A., Sebastião, A. M. & de Mendonça, A. Adenosine receptors in the nervous system: Pathophysiological implications. Prog. Neurobiol. 68, 377-392 (2003).
227. Braganhol, E., Tamajusuku, A. S., Bernardi, A., Wink, M. R. & Battastini, A. M. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim. Biophys. Acta 1770 1352-1359 (2007).
228. 1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res. 66, 8550-8557 (2006).
229. Vianna, E. P., Ferreira, A. T., Doná, F., Cavalheiro, E. A. & da Silva Fernandes, M. J. Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats. Epilepsia 46, 166-173 (2005).
230. 2A receptors of entorhinal cortex on piriform cortex kindled seizures in rats. Pharmacol. Res. 56 110-117 (2007).
231. 1 receptor. Br. J. Pharmacol. 148, 314-325 (2006).
232. Rathbone, M. P. et al. Trophic effects of purines in neurons and glial cells. Prog. Neurobiol. 59, 663-690 (1999).
233. 2A analogue reduces long-term neurologic injury after blunt spinal trauma. J. Surg. Res. 121 130-134 (2004).
234. Mojsilovic-Petrovic, J. et al. Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci. 26, 9250-9263 (2006).
235. Fuxe, K., Ferre, S., Genedani, S., Franco, R. & Agnati, L. F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav. 92, 210-217 (2007).
236. 2A antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) 184, 46-55 (2006).
237. Shields, C. B. et al. Treatment of spinal cord injury via topical perfusion with an ATP solution. Society for Neuroscience, Washington, DC. Abstr. 418, 8 (2004).
238. Cakir, E., Baykal, S., Karahan, S. C., Kuzeyli, K. & Uydu, H. Acute phase effects of ATP-MgCl2 on experimental spinal cord injury. Neurosurg. Rev. 26, 67-70 (2003).
239. Kim, D. S., Kwak, S. E., Kim, J. E., Won, M. H. & Kang, T. C. The co-treatments of vigabatrin and P2X receptor antagonists protect ischemic neuronal cell death in the gerbil hippocampus. Brain Res. 1120, 151-160 (2006).
240. Lin, Y., Desbois, A., Jiang, S. & Hou, S. T. P2 receptor antagonist PPADS confers neuroprotection against glutamate/NMDA toxicity. Neurosci. Lett. 377, 97-100 (2005).
241. Wang, Y. et al. Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J. Neurosci. 23, 7958-7965 (2003).
242. Morrone, F. B. et al. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer 6, 226 (2006).
243. Waeber, C. & Moskowitz, M. A. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61, S9-20 (2003).
244. 7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 46 3378-3385 (2002).
245. 7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc. Natl Acad. Sci. USA. 101, 3214-3219 (2004).
246. 7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319, 1376-1385 (2006).
247. 7 receptor function and indicates a role in chronic pain states. Br. J. Pharmacol. 151, 571-579 (2007).